Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03099980

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Sponsor: Tufts Medical Center

Conditions Hidradenitis Suppurativa

Interventions secukinumab

Updated 6 times since 2017 Last updated: May 31, 2019 Started: Jul 11, 2016 Primary completion: Dec 31, 2018 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03099980, this EARLY_PHASE1 trial focuses on Hidradenitis Suppurativa and remains completed. Sponsored by Tufts Medical Center, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jul 2019 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Jun 2018 — Jul 2019 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

May 2017 — Jun 2018 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tufts Medical Center

Data source: Tufts Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States